Tolrestat
From Self-sufficiency
| File:Tolrestat.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbothioyl}-N-methylglycine | |
| Identifiers | |
| CAS Number | 82964-04-3 |
| ATC code | A10XA01 (WHO) |
| PubChem | CID 53359 |
| Chemical data | |
| Formula | C16H14F3NO3S |
| Molar mass | 357.34 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor[1] which was approved for the control of certain diabetic complications.[2]
While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Withdrawn drugs
- Naphthalenes
- Organofluorides
- Phenol ethers
- Gastrointestinal system drug stubs
- 2Fix
